Francis Medical has announced further expansion of commercial procedures using its Vanquish Water Vapour Ablation system, a minimally invasive technology designed to ablate prostate tissue. The development reflects increasing clinical interest in alternatives to conventional prostate treatments that can reduce invasiveness while preserving quality of life for patients.

The system addresses a major unmet need in prostate disease management: the challenge of effectively treating prostate tissue while minimising complications commonly associated with surgery or radiation therapy. Traditional approaches may lead to significant side effects, including urinary dysfunction and impacts on sexual health, creating demand for less invasive treatment modalities.

Vanquish differentiates itself through the use of targeted water vapour ablation technology, which delivers thermal energy directly into prostate tissue. The approach is intended to selectively destroy diseased tissue while limiting damage to surrounding anatomical structures. By focusing on precision and minimally invasive delivery, the system aims to improve patient recovery and procedural tolerability.

The company highlighted continued expansion of commercial procedures as an indicator of growing physician adoption and operational readiness. The technology is currently progressing through broader clinical utilisation, building on prior development and validation efforts within the urology space.

This solution is targeted at patients with prostate disease requiring tissue ablation, as well as urologists seeking alternatives to more invasive interventions. The increasing prevalence of prostate conditions alongside rising demand for outpatient and minimally invasive procedures is contributing to interest in technologies that can reduce treatment burden while maintaining efficacy.